Strs Ohio Scholar Rock Holding Corp Transaction History

Strs Ohio

$26.2 Billion
Q3 2025

A detailed history of Strs Ohio transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Strs Ohio holds 1,700 shares of SRRK stock, worth $64,294. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,700

Previous 3,900 56.41%

Holding current value

$64,294

Previous $138,000 54.35%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 30, 2025	SELL	$30.12 - $42.86 $66,264 - $94,292	-2,200 Reduced 56.41%	1,700 $63,000
Q2 2025 Aug 04, 2025	BUY	$24.47 - $36.39 $36,705 - $54,585	1,500 Added 62.5%	3,900 $138,000
Q1 2025 May 28, 2025	BUY	$32.15 - $45.55 $77,160 - $109,320	2,400 New	2,400 $77,000
Q2 2022 Jul 25, 2022	SELL	$4.66 - $13.96 $10,252 - $30,712	-2,200 Closed	0 $0
Q3 2021 Oct 22, 2021	SELL	$27.38 - $42.21 $227,254 - $350,343	-8,300 Reduced 79.05%	2,200 $72,000

Q2 2021 Jul 26, 2021	BUY	$26.34 - $46.62 $26,340 - $46,620	1,000 Added 10.53%	10,500 $303,000
Q1 2021 Apr 23, 2021	SELL	$45.96 - $68.02 $363,084 - $537,358	-7,900 Reduced 45.4%	9,500 $481,000
Q4 2020 Jan 25, 2021	SELL	$13.72 - $51.57 $17,836 - $67,041	-1,300 Reduced 6.95%	17,400 $844,000
Q3 2020 Dec 14, 2020	SELL	$10.54 - $18.47 $75,888 - $132,984	-7,200 Reduced 27.8%	18,700 $330,000
Q2 2020 Jul 23, 2020	BUY	$10.37 - $20.64 $21,777 - $43,344	2,100 Added 8.82%	25,900 $471,000
Q2 2019 Jul 25, 2019	BUY	$14.61 - $22.45 $321,420 - $493,900	22,000 Added 1222.22%	23,800 $377,000
Q3 2018 Oct 19, 2018	BUY	$13.39 - $26.25 $24,102 - $47,250	1,800 New	1,800 $46,000

Others Institutions Holding SRRK

# of Institutions

278

Shares Held

101M

Call Options Held

2.02M

Put Options Held

2.23M

View Full List

About Scholar Rock Holding Corp

Ticker SRRK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,640,600
Market Cap $1.95B
Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...

More about SRRK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.

Account